uniQure (NASDAQ:QURE) Receives “Buy” Rating from Chardan Capital
uniQure (NASDAQ:QURE – Get Free Report)‘s stock had its “buy” rating reaffirmed by analysts at Chardan Capital in a research note issued to investors on Friday,Benzinga reports. They currently have a $38.00 price target on the biotechnology company’s stock. Chardan Capital’s target price would indicate a potential upside of 160.99% from the stock’s previous close. […]
uniQure (NASDAQ:QURE – Get Free Report)‘s stock had its “buy” rating reaffirmed by analysts at Chardan Capital in a research note issued to investors on Friday,Benzinga reports. They currently have a $38.00 price target on the biotechnology company’s stock. Chardan Capital’s target price would indicate a potential upside of 160.99% from the stock’s previous close. […]
